

Seat No.: \_\_\_\_\_

Enrolment No. \_\_\_\_\_

**GUJARAT TECHNOLOGICAL UNIVERSITY****M. Pharm. – SEMESTER – III • EXAMINATION – WINTER 2013****Subject Code: 930102****Date: 11-12-2013****Subject Name: Novel Drug Delivery System Part-II****Time: 10.30 am - 01.30 pm****Total Marks: 80****Instructions:**

1. Attempt any five questions.
2. Make suitable assumptions wherever necessary.
3. Figures to the right indicate full marks.

- |             |     |  |           |
|-------------|-----|--|-----------|
| <b>Q.1</b>  | (a) | What is polymer? How are they characterized from other class of excipient? Classify them on the basis of their pharmaceutical analysis.                | <b>06</b> |
|             | (b) | Two major classes of polymers are used in NDDS. Compare and comment giving suitable examples based on their IIG status and impurity profile.           | <b>05</b> |
|             | (c) | Write a note on biodegradation of polymers.  | <b>05</b> |
| <b>Q.2</b>  | (a) | What is the difference between conventional dosage form and NDDS? How an administration device become part of it?                                      | <b>06</b> |
|             | (b) | Define “ Prodrug” Write a note on application of it in therapeutics giving suitable example.   | <b>05</b> |
|             | (c) | Write a note on any one approach to develop prodrug.   | <b>05</b> |
| <b>Q.3</b>  | (a) | What are the basic technologies of developing NDDS? Classify them on the basis of their involvement into different unit operations.                    | <b>06</b> |
|             | (b) | Define “-----Somes” e.g. niosome. Compare hepatic bye-pass vs phagocytic uptake from different route of administration in terms of bioavailability.    | <b>05</b> |
|             | (c) | Write a note on SCF technology.  | <b>05</b> |
| <b>Q.4</b>  | (a) | What is bioadhesion? How does it differs from mucoadhesion? Suggest suitable bodysites to develop these dosage forms.                                  | <b>06</b> |
|             | (b) | How will you balance dissolution/ penetration profile in order to achieve best bioavailability?  | <b>05</b> |
|             | (c) | Write a note on in-situ gels.  | <b>05</b> |
| <b>Q.5</b>  | (a) | Differentiate strips/diskettes and films from their physical, chemical and therapeutic aspects.  | <b>06</b> |
|             | (b) | Write a note on packaging, handling and evaluation of these systems.   | <b>05</b> |
|             | (c) | Write a note on transdermal patch with their extensional aspects.  | <b>05</b> |
| <b>Q. 6</b> | (a) | What do you mean by intelligent drug delivery? Throw a light on different mechanisms to develop them.  | <b>06</b> |
|             | (b) | What is nanotechnology? How it can be applied to drug delivery and suggest any one market product developed on this basis.                             | <b>05</b> |
|             | (c) | What is the future of tailor made medicines in the Indian market?  | <b>05</b> |
| <b>Q.7</b>  | (a) | Define PEGylation. What challenges are overcome by a F & D pharmacist in handling proteins and peptides to deliver to human body using this technique. | <b>06</b> |
|             | (b) | What is immune modulation? Enlist such drugs developed in Indian market.   | <b>05</b> |
|             | (c) | Use of energy NDDS: Comment and explain giving suitable illustration.  | <b>05</b> |

\*\*\*\*\*